Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILENCED: LEAP2 and Semaglutide in Obesity
NCT07171723Phase 1Completed
- Sponsor
- Gentofte Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing LEAP2 with Placebo (2 arms). Primary endpoint: Total energy intake during a standardized ad libitum meal. Started Sep 2025; status: completed.
02
Drugs
liver-expressed antimicrobial peptide 2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07171723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171723.